RxDoctor Payments Data

Helen Yates

Gerontology · Fayetteville, NCNPI 1487264370

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations.

$621in general payments, 2019–2025

Across 31 payments — averaging $20.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$128
  • GSK$90
  • Novo Nordisk$85
  • Bayer$73
  • AstraZeneca$60
  • Boehringer Ingelheim$31
  • plus $154 from 8 others

What the payments were for

  • Food & beverage$621100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$621 in reported general payments places this provider in the 65th percentile of 165 gerontology providers in North Carolina.

See all gerontology providers in North Carolina

Medicare billing

Part B allowed, 2024
$2,879
Medicare patients
19
Services billed
91

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide22$28,276
EntrestoSacubitril/Valsartan17$20,865
TrulicityDulaglutide17$18,329
Albuterol Sulfate HfaAlbuterol Sulfate34$1,328
Ezetimibe35$867
Levothyroxine Sodium43$851
Omeprazole38$752
Atorvastatin Calcium69$718
Rosuvastatin Calcium55$618
Gabapentin24$456
Fluticasone Propionate26$428
Pantoprazole Sodium36$347
Metoprolol Succinate42$345
Amlodipine Besylate54$308
Losartan Potassium43$252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$85$28,27622 claims
NovartisEntresto$18$20,86517 claims
Lilly USA, LLCTrulicity$128$18,32917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 165 gerontology providers in North Carolina.

Other gerontology in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →